Read by QxMD icon Read

Advances in Therapy

Michael H Kim, Liou Xu, Gary Puckrein
INTRODUCTION: Anticoagulants are effective for stroke prevention in atrial fibrillation (AF). Data on population health-related cardiovascular outcomes by race/ethnicity and gender are not well described. The aim was to assess the impact of patient diversity on associated cardiovascular outcomes related to warfarin anticoagulation in Medicare beneficiaries with AF. METHODS: Medicare administrative claims data for years 2000-2010 were used to calculate AF prevalence and rates of new AF cases...
September 15, 2018: Advances in Therapy
Giulia Fornasier, Sara Francescon, Paolo Baldo
Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug...
September 14, 2018: Advances in Therapy
Shichuan Zhang, Chengping Hu, Rongli Lu, Ruichao Niu, Xinyue Hu, Ling Qin, Ruoxi He, Juntao Feng
INTRODUCTION: A significant bronchodilator response is commonly defined as a 12% or greater and 200 ml or greater change in FEV1 from baseline according to the 2005 American Thoracic Society (ATS)/European Respiratory Society (ERS) criterion. A number of studies have shown that the ATS/ERS criterion has limitations in asthma diagnosis, and some experts have argued for correcting the criteria. The aim of this study is to investigate the diagnostic value of acute bronchodilator response for asthma in a Southern Chinese population...
September 12, 2018: Advances in Therapy
Sunnie Kim, James E Signorovitch, Hongbo Yang, Oscar Patterson-Lomba, Cheryl Q Xiang, Brian Ung, Monika Parisi, John L Marshall
INTRODUCTION: nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited. METHODS: This retrospective cohort study compared the efficacy and safety of 1L nab-P + G versus FFX, overall and under specific treatment sequences. Medical records were reviewed by 215 US physicians who provided information on MPAC patients who initiated 1L therapy with nab-P + G or FFX between April 1, 2015 and December 31, 2015...
September 12, 2018: Advances in Therapy
Molly F Purser, Deirdre M Mladsi, Alan Beckman, Francesca Barion, John Forsey
The article "Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy", written by Molly F. Purser, Deirdre M. Mladsi, Alan Beckman, Francesca Barion, John Forsey was originally published electronically on the publisher's internet portal (currently SpringerLink) on August 24, 2018 without open access.
September 12, 2018: Advances in Therapy
Robert B Raffa, Christian Elling, Thomas M Tzschentke
INTRODUCTION: The distinct properties of the centrally-acting analgesic tapentadol derive from the combined contributions of an opioid component and a nonopioid component. However, the opioid component's relative contribution to analgesic and adverse effects has not previously been elucidated. Tapentadol's analgesic effect derives from the combined contribution of an opioid mechanism and a nonopioid mechanism, the extent of which can vary for different pains. Likewise, the interaction can vary for various adverse effects...
September 11, 2018: Advances in Therapy
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya, Michael S Broder
INTRODUCTION: Few studies have compared adherence between long-acting injectable antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (AOM 400; aripiprazole monohydrate) and oral antipsychotics, in patients with schizophrenia or bipolar I disorder (BD-I) in a real-world setting. METHODS: Two separate retrospective cohort analyses using Truven MarketScan data from January 1, 2012 to June 30, 2016 were conducted to compare medication adherence and discontinuation in patients with schizophrenia or BD-I who initiated treatment with AOM 400 vs...
September 11, 2018: Advances in Therapy
Roger A Edwards, Gianluca Bonfanti, Roberto Grugni, Luigi Manca, Bruce Parsons, Joe Alexander
INTRODUCTION: Prediction of final clinical outcomes based on early weeks of treatment can enable more effective patient care for chronic pain. Our goal was to predict, with at least 90% accuracy, 12- to 13-week outcomes for pregabalin-treated painful diabetic peripheral neuropathy (pDPN) patients based on 4 weeks of pain and pain-related sleep interference data. METHODS: We utilized active treatment data from six placebo-controlled randomized controlled trials (n = 939) designed to evaluate efficacy of pregabalin for reducing pain in patients with pDPN...
September 11, 2018: Advances in Therapy
Hirofumi Ochi, Masaaki Niino, Yasuhiro Onizuka, Katsutoshi Hiramatsu, Masakazu Hase, Jang Yun, André Matta, Shinichi Torii
INTRODUCTION: The long-term safety of dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis (RRMS) has been studied in mainly Caucasian patients. The present interim analysis aimed to evaluate the 72-week safety of DMF in Japanese patients with RRMS. METHODS: Safety data of Japanese subjects enrolled in the 24-week randomised, double-blind, placebo-controlled APEX study (Part I) and its following open-label extension (Part II) were analysed at 72 weeks from the beginning of Part I...
September 11, 2018: Advances in Therapy
Olga Růžičková, Zdenko Killinger, Petr Kasalický, Lisa Hamilton, Roman Tyl, Soňa Tomková, Lama Kalouche-Khalil
INTRODUCTION: Osteoporosis is characterized by low bone mineral density (BMD) and an increased risk of fracture. In randomized controlled trials, denosumab has been shown to significantly reduce the fracture risk in women with osteoporosis. However, little is known about the real-world management of women who are prescribed denosumab. METHODS: This multicenter, prospective, observational real-world study in the Czech Republic and Slovakia evaluated the baseline characteristics and clinical management of women with postmenopausal osteoporosis prescribed denosumab for 24 months...
September 6, 2018: Advances in Therapy
Ian P Naya, Lee Tombs, David A Lipson, Chris Compton
INTRODUCTION: Assessing clinically important measures of disease progression is essential for evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease (COPD). This analysis assessed whether providing additional bronchodilation with the long-acting muscarinic antagonist umeclidinium (UMEC) to patients treated with inhaled corticosteroid (ICS)/long-acting β2 -agonist (LABA) therapy would improve disease stability compared with ICS/LABA therapy alone...
September 6, 2018: Advances in Therapy
Neil M Schultz, Scott C Flanders, Samuel Wilson, Bruce A Brown, Yan Song, Hongbo Yang, Stanislav Lechpammer, Vahan Kassabian
INTRODUCTION: Enzalutamide and abiraterone acetate (plus prednisone) are new hormonal treatments for metastatic castration-resistant prostate cancer (mCRPC). This study compared treatment duration, healthcare resource utilization (HRU), and treatment costs for chemotherapy-naïve mCRPC patients treated with enzalutamide or abiraterone acetate in the USA. METHODS: Chemotherapy-naïve mCRPC patients initiating treatment with enzalutamide or abiraterone acetate were identified from administrative claims...
September 6, 2018: Advances in Therapy
Andrew Menzies-Gow, G-Walter Canonica, Tonya A Winders, Jaime Correia de Sousa, John W Upham, Antje-Henriette Fink-Wagner
Severe asthma is a subtype of asthma that is difficult to treat and control. By conservative estimates, severe asthma affects approximately 5-10% of patients with asthma worldwide. Severe asthma impairs patients' health-related quality of life, and patients are at risk of life-threatening asthma attacks. Severe asthma also accounts for the majority of health care expenditures associated with asthma. Guidelines recommend that patients with severe asthma be referred to a specialist respiratory team for correct diagnosis and expert management...
September 4, 2018: Advances in Therapy
Marco Calabrò, Laura Mandelli, Concetta Crisafulli, Soo-Jung Lee, Tae-Youn Jun, Sheng-Min Wang, Ashwin A Patkar, Prakash S Masand, Francesco Benedetti, Changsu Han, Chi-Un Pae, Alessandro Serretti
INTRODUCTION: Mood disorders are common and disabling disorders. Despite the availability of over 100 psychotropic compounds, only one-third of patients benefit from first-line treatments. Over the past 20 years, many studies have focused on the biological factors modulating disease risk and response to treatments, but with still inconclusive data. In order to improve our current knowledge, in this study, we investigated the role of a set of genes involved in different pathways (neurotransmission, neuroplasticity, circadian rhythms, transcription factors, signal transduction and cellular metabolism) in the treatment outcome of major depressive disorder (MDD) and bipolar disorder (BD) after naturalistic pharmacological treatment...
September 3, 2018: Advances in Therapy
Anna Theodorou-Kanakari, Spyridon Karampitianis, Vasiliki Karageorgou, Eleni Kampourelli, Efstathios Kapasakis, Panagiotis Theodossiadis, Irini Chatziralli
INTRODUCTION: The purpose of this review is to present the current and emerging treatment alternatives for Leber's hereditary optic neuropathy (LHON), emphasizing the most recent use of idebenone and stem cells or gene therapy. METHODS: A comprehensive literature review was performed at the PubMed database regarding the various treatment modalities for LHON. RESULTS: Treatment modalities for LHON include nutritional supplements, activators of mitochondrial biogenesis, brimonidine, and symptomatic and supportive treatment, but nowadays attention is being paid to idebenone and gene therapy or stem cells...
September 1, 2018: Advances in Therapy
Sanjay Kalra, A K Das, Sarita Bajaj, Banshi Saboo, Deepak Khandelwal, Mangesh Tiwaskar, Navneet Agarwal, Pritam Gupta, Rakesh Sahay, Sameer Aggarwal, Sujoy Ghosh, Vijay Negalur, A G Unnikrishnan, Ganapathi Bantwal, Rashmi Aggarwal, Harshal Chaudhari, Nitin Mulgaonkar
Hypothyroidism presents a large epidemiological burden in India. As a result of subtle and nonspecific clinical symptoms and signs, the condition often goes undiagnosed and is not adequately treated when it is detected. There is heterogeneity in the diagnostic and treatment approaches to hypothyroidism. As a result of the physiological changes in thyroid hormones with age and illness, it is important to tailor the diagnosis and management of this condition in specific populations including pregnant women, infants, children, geriatric patients, and those with comorbid conditions...
August 31, 2018: Advances in Therapy
Karen Seiter, Dominick Latremouille-Viau, Annie Guerin, Briana Ndife, Karen Habucky, Derek H Tang, Irina Pivneva, Patrick Gagnon-Sanschagrin, George J Joseph
INTRODUCTION: Tyrosine kinase inhibitors (TKI) have been demonstrated to prolong survival in patients with chronic myeloid leukemia (CML). However, TKIs may be associated with an increased risk of infections. This study compared healthcare resource utilization (HRU) and costs among patients with CML receiving dasatinib or nilotinib, with a focus on infection-related economic outcomes. METHODS: Two large administrative databases were used to identify adult patients newly diagnosed with CML who initiated dasatinib or nilotinib as first- (1L) or second-line (2L) therapy and were classified into the following 1L (dasatinib 1L/nilotinib 1L cohorts) or 2L (dasatinib 2L/nilotinib 2L) cohorts based on the initiated 1L/2L TKI therapy...
August 28, 2018: Advances in Therapy
Molly F Purser, Deirdre M Mladsi, Alan Beckman, Francesca Barion, John Forsey
INTRODUCTION: The objective was to estimate, from the perspective of a managed care organization in the United States, the budget impact and effect on health outcomes of expanded use of vagus nerve stimulation [VNS (VNS Therapy® )] among patients aged ≥ 12 years with drug-resistant epilepsy (DRE) with partial-onset seizures. METHODS: An Excel model was developed to compare the costs of continued anti-epileptic drug (AED) treatment with the costs of VNS plus AED treatment...
August 24, 2018: Advances in Therapy
Elena A Zheleznykh, Yulia A Danilogorskaya, Elena V Privalova, Yury N Belenkov, Anastasia A Schendrygina, Irina S Chekneva, Nikolay A Pavlov, Mikhail I Tishman
INTRODUCTION: The objective of this study was to assess the impact of a single-pill combination (SPC) of perindopril/indapamide (PER/IND) at full doses (10/2.5 mg) on endothelial and cognitive function as a clinical intermediate marker of vascular improvement. METHODS: This open-label, uncontrolled, observational study enrolled 30 patients (20 females and 10 males) with grade II-III uncontrolled arterial hypertension (SBP/DBP ≥ 160/100 mmHg) and no evidence of cerebrovascular disease...
August 20, 2018: Advances in Therapy
Paul Emery, Janet E Pope, Klaus Kruger, Ralph Lippe, Ryan DeMasi, Sadiq Lula, Blerina Kola
Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with methotrexate in the treatment of rheumatoid arthritis (RA), up to one-third of patients with RA are treated with monotherapy. The objective of the systematic literature review reported here was to evaluate the clinical evidence regarding the efficacy of b/tsDMARDs as monotherapy in the treatment of RA. MEDLINE® , Embase® , and the Cochrane Central Trials Register (to April 11, 2017) and the American College of Rheumatology and European League Against Rheumatism conference proceedings (2010-2016) were searched for randomized controlled trials evaluating the efficacy of b/tsDMARDs as monotherapy for RA in adults...
August 20, 2018: Advances in Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"